Latest news with #AS
Yahoo
a day ago
- Sport
- Yahoo
Spanish outlet highlights Atlético Madrid's interest in Woltemade
After just one season at VfB Stuttgart, Nick Woltemade could be on the move again this summer if reports are accurate. According to the Spanish newspaper "AS," Atlético Madrid is said to be interested in the Swabians' towering marksman. The report suggests the club from the Spanish capital is willing to sign the German international if they can find a buyer for Correa. Woltemade's flexibility, coupled with his ability on the ball and clinical edge, are listed as reasons for Atlético's interest. Whether Woltemade will leave VfB Stuttgart, however, is questionable. He currently has a contract with the Bundesliga club until 2028.
Yahoo
2 days ago
- Business
- Yahoo
Evercore ISI Keeps Buy Rating on Amer Sports (AS), Lifts PT
In a report released on May 21, Michael Binetti from Evercore ISI maintained a Buy rating on Amer Sports, Inc. (NYSE:AS) and raised its price target to $43 from $36. The rating came after the company released strong fiscal Q1 2025 results on May 20, raising its full-year revenue and EPS guidance. Amer Sports, Inc. (NYSE:AS) experienced a notable 23% sales growth in fiscal Q1 2025, or 26% excluding currency effects. Its adjusted operating margin also expanded by around 500 basis points. The positive trends highlight the company's strategic focus on boosting its market reach and increasing profitability, which is why analysts are bullish on the stock. A group of professional athletes wearing the company's performance apparel in a sports event. The key drivers of positive performance for Amer Sports, Inc. (NYSE:AS) in the quarter were its Technical Apparel and Outdoor Performance segments. Technical Apparel rose 28% to $664 million (or 32% on a constant currency basis), while Outdoor Performance grew 25% to $502 million (or 29% on a constant currency basis). The numbers reflect strong demand for its products, supporting the optimistic sentiment. Amer Sports, Inc. (NYSE:AS) plans to continue this momentum and anticipates revenue growth of 15% to 17% for fiscal year 2025. While we acknowledge the potential of AS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AS and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None.
Yahoo
4 days ago
- Business
- Yahoo
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
At the EuroPCR 2025, Edwards Lifesciences EW has announced new economic and clinical evidence on severe aortic stenosis (AS). The results of a new real-world study, comprising more than 24,000 patients, demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes. Presented as a late-breaking clinical trial, the data further contributes to the extensive body of research on this disease. The development is expected to boost both the company's Transcatheter Aortic Valve Replacement ('TAVR') and Surgical Structural Heart business units. Yesterday, Edwards shares finished the session at $74.79, down 1.7% from the previous close. On a promising note, the company has been committed to TAVR innovation and high-quality science that is increasing access to treatment options for all AS patients. Robust clinician adoption of the SAPIEN technology backs the segment's growth. In Surgical, Edwards continues to benefit from the strong uptake of the premium RESILIA portfolio, including INSPIRIS, MITRIS and KONECT. The company has been steadily advancing its top-tier surgical innovations around the world, solidifying its position. Hence, we expect that the market sentiment around EW stock will remain positive, driven by the latest news. Irvine, CA-based Edwards Lifesciences boasts a market capitalization of $44.64 billion. The company's earnings yield of 3.2% favorably compares to the industry's -2.8% yield. It has delivered an earnings beat of 3.5%, on average, in the trailing four quarters. The study revealed that prompt intervention for severe AS patients before symptoms developed has resulted in $36,000 less cost per patient for the healthcare system in one year. The length of hospital stay during treatment is shorter by 2.2 days, while follow-up heart failure hospitalizations one year after treatment also dropped by 80%. Additionally, compared with asymptomatic severe AS, delaying treatment until the disease progressed led to a more than seven times higher rate of death within one year after aortic valve replacement (AVR). Image Source: Zacks Investment Research Together with the previous data from the EARLY TAVR trial, these results have reinforced the value of early referral and evaluation by a Heart Valve Team for all patients with severe AS. Per a Market Research Future report, the AS treatment market is estimated at $8.6 billion in 2024 and projected to witness a compound annual growth rate (CAGR) of 7.4% by 2034. The market growth is highly driven by the advancements in medical technology, including minimally invasive procedures and breakthrough devices. Furthermore, the growing awareness among healthcare professionals and patients about treatment options is also leading to the market's expansion as more individuals seek early intervention for their conditions. This month, Edwards received FDA approval for its TAVR therapy, the SAPIEN 3 platform, meant for severe AS patients without symptoms. The approval is based on the groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance. In April, the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. In the past six months, shares of EW have risen 5% against the industry's 11.8% fall. Edwards currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 24.1% in the past year compared with the industry's 8.6% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have rallied 217.1% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare'sfiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 36.8% in the past year compared with the industry's 10.8% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Upturn
4 days ago
- Business
- Business Upturn
VIBGYOR Group of Schools Celebrates Stellar Cambridge Results
Mumbai, Maharashtra, India: IGCSE and A Level scores reaffirm VIBGYOR's commitment to global, future-ready education Cambridge offering at the recently launched World Academy in Bhopal and Nagpur is set to mirror VIBGYOR's global academic vision VIBGYOR Group of Schools, a leading network of K-12 institutions in India, proudly announces the outstanding performance of its students in the Cambridge (CIE) IGCSE (Grade 10), AS (Grade 11), and A Level l (Grade 12) examinations for the academic year 2024–25. These stellar results reflect VIBGYOR's progressive educational vision, international benchmarks, and steadfast commitment to nurturing globally competent learners. The achievement is particularly meaningful as Indian families increasingly seek globally aligned academic pathways. With the international education sector growing steadily, marked by a 14% rise in international schools, a 40% surge in student enrollment, and a 36% increase in staff recruitment over the past five years, according to the ISC research. There is a clear shift toward education that goes beyond rote learning. In this context, the newly launched VIBGYOR World Academy in Bhopal and Nagpur, offering the Cambridge curriculum, stands out as a preferred choice for parents focused on nurturing 21st-century skills such as critical thinking, collaboration, creativity, and digital fluency. What differentiates VIBGYOR's approach is how seamlessly it integrates the strengths of the Cambridge curriculum into its educational framework. Known for its flexibility and global relevance, the Cambridge system encourages students to engage with real-world problems, apply interdisciplinary knowledge, and demonstrate their learning through coursework and projects, not just exams. At VIBGYOR World Academy, this is further elevated through the use of Apple-enabled digital classrooms, immersive co-curricular activities, and a personalised learning model that puts student interests and potential at the centre. The result of this integrated approach is evident in the academic excellence achieved across VIBGYOR campuses. Students secured numerous A* and A grades, with several earning subject distinctions—a reflection not only of their hard work, but also of the environment that supports their growth intellectually, emotionally, and creatively. 'It gives me great pride to see how well our Cambridge students thrive on a curriculum that demands both academic rigour and intellectual independence,' said Kavita Kerawalla, Vice-Chairperson, VIBGYOR Group of Schools. 'These results go beyond traditional markers of success, they represent a global outlook, critical thinking abilities and adaptability that our students develop through the Cambridge pathway. My heartfelt congratulations to each of them and gratitude to our educators and parents who enabled this journey.' Toppers for IGCSE: Rank Name of the student Centre Percentage No. of A* 1 Aditya Ashwin Aina NIBM 93.60% 8 2 Krish Gopal Pandit Goregaon 93.50% 7 3 Jeet Pankaj Vassal Goregaon 92.88% 7 Toppers for A levels: Rank Name of the student Centre Percentage No. of A* 1 Vedant Bhatt NIBM 91.7% 3 1 Varun Venkatasalam Marathahalli 91% 3 3 Siddh Gandhi NIBM 90.3% 2 VIBGYOR World Academy, located in Nagpur and Bhopal, offers the Cambridge curriculum through a unique combination of academic excellence and technology-enhanced classrooms. These Apple-enabled environments support a rich, interactive learning experience and promote inquiry-based teaching. The Academy is designed to foster critical thinking, creativity, and global citizenship, preparing students for academic success and leadership in a rapidly changing world. About VIBGYOR Group of Schools Founded in 2004, VIBGYOR Group of Schools, recognised as Best Education Brand of 2024 by The Economic Times, followed by the BW Education Top Education Brands Award 2024 for Academic Excellence in K-12, is a leading network of K-12 schools known for its academic excellence for over two decades. The Group offers a unique range of world-class educational programs for the holistic development of students in curricular and co-curricular studies across all its schools. Under the leadership of Mr. Rustom Kerawalla, Founder Chairman of the institution, VIBGYOR Group of Schools is nurturing the academic growth and development of over 50,000 students nationwide across its 39 schools in 15 major cities. VIBGYOR Group of Schools delivers international levels of education in affiliation with CISCE, CBSE and Cambridge International curriculum, from early years education to Grade 12. Advertisement Submit your press release Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
5 days ago
- Business
- Yahoo
Why Amer Sports, Inc. (AS) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where Amer Sports, Inc. (NYSE:AS) stands against other stocks that skyrocketed today. Ten companies boasted whopping gains on Tuesday despite a wider market pessimism, as a flurry of corporate developments, including impressive earnings and bullish outlooks, sparked buying appetite. In contrast, Wall Street's main indices all finished in the red territory. The Dow Jones was down by 0.27 percent, the S&P 500 dropped 0.39 percent, and the tech-heavy Nasdaq declined 0.38 percent. In this article, we named the 10 best-performing stocks during the trading session and detailed the reasons behind their gains. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. Photo by Jannik Skorna on Unsplash Amer Sports saw its share prices increase by 19.05 percent on Tuesday to close at $37.37 apiece following an impressive earnings performance in the first quarter of the year. In a statement, Amer Sports, Inc. (NYSE:AS) said revenues increased by 23 percent to $1.47 billion from $1.19 billion in the same period last year. Net income, on the other hand, skyrocketed by 1,901 percent to $138.1 million from only $6.9 million in the same comparable period. Earnings per share ended at 24 cents, versus only 1 cent year-on-year. Amer Sports, Inc. (NYSE:AS) said it is targeting to grow its revenues by 15 to 17 percent and fully diluted EPS between 67 and 72 cents during the full-year period, assuming US import tariffs on China remain at 30 percent, and the rest of the world at 10 percent. Meanwhile, second quarter revenue growth is pegged at 16 to 18 percent, with fully diluted EPS at 2 cents. Overall, AS ranks 10th on our list of today's best-performing stocks. While we acknowledge the potential of AS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AS and that has 100x upside potential, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
